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Variety is the spice 
of life 
Affymax NY. 
Affymax N.V. in Palo Alto, California, 
is best known for its involvemenr. in 
the field of combinatorial chemistry, 
the group of chemical methods that 
enable huge numbers of diverse 
compounds to be synthesized in a 
defined mixture. Although the 
company has not always been the clear 
leader in the field, it has developed a 
streamlined approach to determining 
the usefulness of the leads it produces. 
Glaxo Wellcome plc’s decision in 
March 1995 to acquire the company for 
$533 million is seen as a testament to 
the value of their approach. “Obviously 
Glaxo thought they were one of the 
leaders in high-throughput screening,” 
says Kim Janda of the Scripps Research 
Institute. “l’he best methodologies are 
all very well, but at the end of the day 
it’s who gets the right drug....and 
Affymax have the horses to do it.” 
A new company 
Affymax was founded in 1989 by Dr 
Alejandro Zaffaroni, a biochemist 
turned biotechnology entrepreneur. 
Increased cloning and expression of 
proteins in the latter half of the 1980s 
introduced a huge number of new 
targets for drug intervention, and 
Zaffaroni conceived the idea of an 
‘affinity matrix’ (the origin of the 
company’s name) to screen for new 
drugs. In essence, this is a way of 
arraying potential l igands in a defined 
format so that the identity of the 
bound ligand can be determined by its 
position in the matrix. “The idea was 
to let the targets find the molecules 
they wanted to interact with,” says 
Mark Gallop, director of combinatorial 
chemistry at Affymax. “We could do 
this by developing technology that 
would allow us to make and screen a 
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large number of compounds in a short 
amount of time.” 
Zaffaroni’s original idea was to 
screen large numbers of marine natural 
products in this spatially addressable 
way. But Affymax scientists later 
decided, with the help of their scientific 
advisors (including Avram Goldstein, 
Stanford liniversity, Peter Schultz, 
LJniversity of California, Berkeley and 
Joshua Lederberg, Rockefeller 
University), to use peptide synthesis to 
generate the molecules for screening. 
Peptides 
The idea that peptides could be 
synthesized using combinatorial 
techniques began with Mario Geysen 
and colleagues in Melbourne, Australia, 
who in 1984 synthesized a limited 
library with each peptide on a separate 
pin. In 198.5, Richard Houghten (then 
at the Scripps Research Institute) 
developed a similar technique using 
mesh containers dubbed tea-bags. Like 
all combinatorial methods, these 
approaches used several sequential 
reactions, performed in parallel, to build 
up each peptide; each step adds one 
amino acid, but the amino acid added is 
different for each pin or teabag. 
Two techniques were developed at 
Affymax to exploit these ideas. Phage 
display was developed simultaneously 
at Affymax, Cetus Corp., and the 
University of Missouri. In this 
technique, shorr. oligonucleotides of 
random sequence are inserted into the 
gene for a phage coat protein, giving 
phage viruses that express a random 
peptide sequence, different for each 
phage, at the tip of the coat protein. 
The second technique, and Affymax’s 
first foray into solid-phase chemical 
synthesis, began with an idea that was, 
says Gallop, “conceptually out of left 
field”. Borrowing the concept of 
photolithography from the nearby 
semiconductor industry, they 
developed VLSIPS (very large scale 
immobil ized polymer synthesis) chips, 
which can be covered with very dense 
arrays of peptides (up to 
50 000 peptides cm-‘). 
Synthesis of peptides on VLSIPS 
starts with glass slides covered with a 
linker group that has an amino 
function. The photolabile protecting 
group on the amino group is removed 
in a spatially controlled way by shining 
light through a mask that allows light to 
reach only some areas of the slide. 
Amino acid analogs (also with a 
photolabile group) can then be coupled 
to just those areas of the slide by 
standard chemistry. By arranging the 
position of the mask appropriately, a 
large number of different peptides can 
be made at known positions on the 
slide. After synthesis of the peptide 
array, the target protein is fluorescentlp 
labeled, allowed to bind to the slide, 
and the location (and therefore the 
structure) of tight binders are identified 
using an epifluorescence microscope. 
Beyond peptides 
By early 1992 it became apparent that 
diverse, polymeric building blocks 
could be made using unnatural 
substrates, such as the peptoids made 
at Chiron Corporation, and the 
protease-resistant polycarbamates thar 
Affymax scientists made using 
activated amino alcohols in 
collaboration with Peter Schultz of the 
Ilniversity of California, Berkeley. 
Also in 1992, Jonathan Ellman and 
colleagues at the [Jniversity of 
California, Berkeley, and Sheila 
Dewitt and the bioorganic group at 
Parke Davis showed that solid-phase 
synthesis could be used to generate 
1,4-benzodiazepines, an example of 
the type of non-polymeric small 
organic molecules traditionally favored 
as drug leads by the pharmaceutical 
industry. (Similar heterocycles have 
proven to be ideal scaffolds, as 
different functionalities can be added 
radially instead of linearly.) Although 
previous workers had shown that solid- 
phase organic synthesis had utility 
beyond peptide and oligonucleotide 
chemistry, this work described 
optimized reaction sequences 
specifically designed to be useful in 
combinatorial synthesis. 
Similar techniques were also being 
developed at Affymax. A common 
starting point for the formation of 
several heterocycles was an imine, 
which is synthesized by the 
condensation of an amino group (on a 
solid support) with aldehydes or 
ketones. ‘Thiolate addition to imines 
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yields thiazolidinones, some of which 
interact with G-protein-coupled 
receptors. Libraries based on this 
chemistry have led to the discovery of 
novel inhibitors of cyclooxygenase 
(COX-1) and antagonists of opioid 
receptors. Imines were also the starting 
point for the generation (via ketene 
addition) of a library of p-lactams, 
potential antibiotics. Addition to 
imines also gives pyrrolidines and 
tetrahydropyridines, nuclei that are 
common in bioactive compounds, and 
a library of pyrrolidines has yielded a 
potent inhibitor of angiotensin 
converting enzyme. Finally, building 
on a hydroxyl rather than an amino 
group allows the synthesis of 
phosphonyl-acid-based libraries that 
may include novel metalloprotease 
inhibitors. Some compounds from 
these synthetic efforts are being tested 
in pre-clinical animal models, although 
none are yet in human trials. 
The libraries 
Combinatorial libraries of organic 
chemicals are generated by sequential 
reactions, each resulting in the addition 
of a small chemical building block to 
the compound. The diversity of the 
library depends on the number and 
combinations of the building blocks 
added at each step. 
Affymax has focussed on solid- 
phase synthesis using beads 
100-200 Frn in diameter. The reactions 
used must therefore be restricted to 
those that will maintain the linkage to 
the bead, but the fact that the beads 
are easy to separate from the reagents 
allows each reaction in a multistep 
synthesis to be driven co completion by 
the use of vast excesses of reagents. 
Libraries of compounds fall into 
two major categories. If there is no 
information as to what type of 
compound might bind the target 
protein a large, structurally diverse 
library of as many as 101o-lO1l peptides 
or 100 000400000 small organic 
molecules is searched. Once a lead has 
been found a local search will then be 
undertaken using a focussed library of 
a few hundred analogs made in parallel 
in 96-well plates, rather than on beads. 
Screening is routinely done in 
solution after chemical or photocleavage. 
Researchers at Affymax have improved 
traditional nicrobenzyl photolinkers by 
alkyl and alkoxy additions, thereby 
shifting the cleavage wavelength out of 
the potentially damaging UV range, 
increasing the rate of photocleavage, 
and decreasing the reactivity of the 
products -lOO-fold. Photocleavage is 
often preferable co chemical cleavage, 
as it is a mild technique that liberates a 
compound directly into an assay. 
Decoding 
Each bead has -ZO@-300 pmoles of 
compound bound to it, just enough for 
mass spectroscopy to be used to 
identify the compound after it has been 
cleaved from the bead. But in general 
the information gained from this 
technique is ambiguous, necessitating 
the development of ocher decoding 
techniques. Several researchers, 
including some at Affymax, suggested 
that the beads could be tagged at each 
synthetic step with a molecule whose 
structure was easier to determine. The 
initial approach at Affymax was to use 
oligonucleocides, which at the end of 
the synthesis could be amplified by the 
polymerase chain reaction (PCR) and 
sequenced, while other groups used 
amino acids and Edman sequencing. As 
oligonucleotides are susceptible to 
degradation in many of the reaction 
conditions used in combinatorial 
chemistry, Affymax has since developed 
more robust methods using secondary 
amine tags, which can be decoded by 
acid hydrolysis followed by HPLC. 
Reaction progress can be rapidly 
monitored without cleavage from solid 
supports using solid-state NMR after 
incorporating 13C-labeled building 
blocks into syntheses. Even more 
sensitive is ‘H. NMR of resin-bound 
molecules using a Varian Nano-NMR 
probe, which allows structure 
determination for very small samples 
using magic-angle spinning. This 
technique, says Chris Holmes, a 
research fellow at Affymax, “brings 
protein NMR into the realms of solid- 
phase synthesis”. 
The future 
Gallop sees the integration of 
chemistry, biology and engineering as 
the key to the continued success of 
Affymax. “Because we have been doing 
this for a long time we can move very 
fast,” he says. For example, a generic 
expression system developed at 
Affymax allows the extracellular 
domains of receptors to be expressed, 
purified by cleavage of a lipid anchor, 
and immobilized using antibodies to a 
common tag for use in assays. “Their 
strength is in interfacing the libraries 
with the biology, ” says Mario Geysen, 
now the head of combinatorial 
chemistry at Glaxo. 
As one major push for many 
combinatorial chemists is the 
automation of synthesis, the depth in 
engineering at Affymax is crucial. 
Engineering will also aid the current 
push cowards miniaturization, which 
will not only conserve reagents, but 
could also stop potential hits from being 
overlooked. With current methods the 
solubilizacion of the contents of a single 
bead in the well of a microtitre plate 
gives a - 1 p,M solution of the 
compound, so potential hits with an 
affinity of -10 FM are missed. 
New companies 
Affymax is now big enough to be 
spawning younger companies. The 
VLSIPS technology is now solely 
developed by Affymetrix Inc., which 
was separately incorporated in 1992. 
Affymecrix has used VLSIPs to build 
DNA probe arrays that can be used for 
genetic tests, including the detection of 
single-base mutations. This technology 
is not, however, being used for small- 
molecule combinatorial chemistry, as 
the necessity for the attachment of 
photolabile groups at every step proved 
coo restrictive on the types of 
functionalities chat could be introduced. 
A second spin-off company, 
Maxygen Inc., is being formed to focus 
on the potentials of the gene shuffling 
technique developed by Pim Stemmer 
at Affymax. In this technique, 
mutations in enzymes are recursively 
generated and recombined, after which 
the enzymes can be selected for novel 
properties such as the ability to 
degrade xenobiotics or synthesize 
novel small molecules. 
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